Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases.

Authors :: Andreev-Drakhlin, Alexander
Cabanillas, Maria
Amini, Behrang
Subbiah, Vivek
Source :: JCO Precision Oncology. 10/30/2020, Vol. 4, p1302-1306. 5p.
Publication Year :: 2020

Subjects :: *MEDULLARY thyroid carcinoma
*HEREDITARY cancer syndromes
*RADIOTHERAPY
*METASTASIS
*CYCLIN-dependent kinase inhibitors
*RADIOSURGERY

Full Text Access

Tools